Skip to main content
Alzheimer's & Dementia logoLink to Alzheimer's & Dementia
. 2025 Jan 9;20(Suppl 9):e094093. doi: 10.1002/alz.094093

Voxel‐wise comparison of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of individuals across the Alzheimer’s disease spectrum – the HEAD study

Bruna Bellaver 1,, Guilherme Povala 1, Guilherme Bauer‐Negrini 1, Firoza Z Lussier 1, Livia Amaral 1, Pamela CL Ferreira 1, Val J Lowe 2, David N soleimani‐meigooni 3, Hwamee Oh 4, Dana Tudorascu 1, William J Jagust 5, William E Klunk 1, Belen Pascual 6, Brian A Gordon 7, Pedro Rosa‐Neto 8, Suzanne L Baker 9, Tharick Ali Pascoal 1
PMCID: PMC11713812

Abstract

Background

In vivo studies using the tau PET tracers have shown high performance for the diagnosis of Alzheimer’s disease dementia and patterns of tracer uptake that resemble those observed in post‐mortem studies. However, tau tracers present distinct patterns of binding that might influence their performance in detecting AD pathology. In a head‐to‐head study, we investigated the performance of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of AD.

Method

We assessed 132 individuals from the HEAD study (58 CU Aß‐, 15 CU Aß+, 14 MCI Aß‐, 32 MCI Aß+ and 13 AD dementia) with Aß‐PET, [18F]MK6240 and [18F]Flortaucipir. Voxel‐wise receiver operating characteristic curves (ROC) of the two tau tracers were used to contrast groups provided the area under the curve (AUC) for disease diagnosis or biomarkers positivity.

Result

The brain maps showed numerically higher and more spread AUC for [18F]Flortaucipir to discriminate CU Aß‐ from CU Aß+ (Fig.1A). The difference between tracers’ AUC was greater in Braaks IV and V (Fig.2A), both regions that are not expected to have tau accumulation in CU Aß+ individuals, reflecting a potential off‐target binding for [18F]Flortaucipir. To differentiate CU Aß‐ from MCI Aß+ individuals, [18F]MK6240 presented a numerically higher AUC than [18F]Flortaucipir in Braak I and II and similar AUC in other Braak regions (Fig.1B, Fig. 2B). We observed a high performance of [18F]MK6240 and [18F]Flortaucipir in differentiating AD dementia from CU Aß‐ individuals. However, [18F]MK6240 exhibits a higher AUC than [18F]Flortaucipir in all Braak regions, especially Braak V‐VI (Fig.1C, Fig.2C). Finally, [18F]MK6240 presented higher AUC in all Braak regions to discriminate MCI Aß‐ from MCI Aß+ individuals (Fig.1D, Fig.2D).

Conclusion

Our results indicate that [18F]MK6240 and [18F]Flortaucipir present high accuracy to discriminate AD from CU Aß‐ individuals. However, [18F]MK6240 presents higher AUC to discriminate AD and MCI Aß+ from CU Aß‐ individuals than [18F]Flortaucipir. Together, our head‐to‐head study sheds light on the distinct patterns of binding for Tau‐PET tracers.


graphic file with name ALZ-20-e094093-g001.jpg

graphic file with name ALZ-20-e094093-g002.jpg


Articles from Alzheimer's & Dementia are provided here courtesy of Wiley

RESOURCES